Merck & Co., Inc. has agreed to acquire Terns Pharmaceuticals, Inc. for about $6.7 billion in equity value, adding TERN-701, an investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor in Phase 1/2 development for chronic myeloid leukemia, to its hematology pipeline. The proposed transaction, expected to close in the second quarter of 2026, signals a more deliberate push by the U.S.-based biopharmaceutical company to build post-Keytruda oncology depth in areas where differentiated assets can still command strategic premiums.
What matters now is not the headline value of the transaction but the specific kind of asset Merck & Co., Inc. is buying. Chronic myeloid leukemia is not a greenfield market. It is one of the most deeply established precision oncology categories in modern medicine, shaped by decades of tyrosine kinase inhibitor development and by steadily rising expectations around response depth, tolerability, and long-term disease control. That means TERN-701 will not be judged merely on whether it works. It will be judged on whether it works fast enough, cleanly enough, and convincingly enough to justify a place in a treatment landscape that already includes multiple established options and an increasingly sophisticated clinical mindset around sequencing.
That is why the acquisition looks less like a classic pipeline expansion and more like a selective bet on mechanism-level differentiation. TERN-701 is designed as an allosteric BCR::ABL1 inhibitor, targeting the ABL myristoyl pocket rather than competing directly at the ATP-binding site. In strategic terms, that matters because allosteric inhibition has already changed how clinicians and drug developers think about resistance, tolerability, and the next phase of chronic myeloid leukemia management. Merck & Co., Inc. is not entering hematology with a generic follow-on candidate. It is buying into a more nuanced therapeutic class where the commercial and clinical upside rests on being meaningfully better, not merely clinically active.
Why Merck’s TERN-701 acquisition suggests oncology portfolio quality matters more than simple scale now
For Merck & Co., Inc., the transaction also fits a broader capital allocation logic that has become more visible across large-cap oncology. The company has been under persistent investor scrutiny over how it will diversify revenue sources before Keytruda faces biosimilar pressure later this decade. Acquiring a clinical-stage chronic myeloid leukemia asset does not solve that revenue concentration issue on its own, but it does reveal a preference for earlier strategic entry into high-conviction science rather than waiting for fully de-risked late-stage assets that may cost even more or attract fiercer competition.
The transaction price reflects that urgency. Paying a multibillion-dollar premium for a Phase 1/2 asset would have looked aggressive in many prior market cycles. In the current environment, it looks more like an expression of scarcity. Large pharmaceutical companies with balance-sheet strength are increasingly competing for assets that offer mechanistic novelty, credible early efficacy, and a clean enough safety signal to support rapid development expansion. Terns Pharmaceuticals, Inc. appears to have offered that combination, even if the program remains early by regulatory standards.
There is also a portfolio-shaping logic here. Merck & Co., Inc. has already been expanding its hematology pipeline with assets spanning leukemias, lymphomas, and myeloproliferative neoplasms. TERN-701 gives the drugmaker another foothold in a category where targeted therapy biology is well understood, trial pathways are clearer than in some solid tumors, and clinical differentiation can be visible relatively early if the data are strong enough. In other words, this is not just a science bet. It is a category bet on a disease area where execution risk may be more manageable than in broader, noisier oncology settings.
Why the chronic myeloid leukemia market still leaves room for new entrants despite decades of TKI progress
At first glance, chronic myeloid leukemia may appear crowded and mature. That is precisely why the remaining opportunity is clinically interesting. The field has moved far beyond the original breakthrough era of BCR::ABL1 inhibition. Physicians now focus not only on hematologic or cytogenetic control, but on molecular response kinetics, durability, mutation coverage, treatment tolerability, and the possibility of treatment-free remission for selected patients. As standards rise, the bar for new therapies rises with them, but so does the reward for any drug that can demonstrate a better balance of potency and tolerability.
According to the source material, TERN-701 has shown promising activity in early clinical testing, including encouraging rates of major molecular response and deep molecular response by week 24, with signals seen even in patients who had received multiple prior lines of therapy, including prior exposure to an allosteric tyrosine kinase inhibitor. The release also described the adverse event profile as largely low grade, with low rates of severe events and discontinuations, no clinically meaningful blood pressure changes, and limited lipase elevation.
Those data points are directionally important, but they are not yet definitive. Early response signals in chronic myeloid leukemia can be commercially and clinically meaningful, particularly if they emerge in harder-to-treat patients. But the market has seen many oncology programs generate enthusiasm before larger datasets clarified the true magnitude and durability of benefit. The central question is whether TERN-701 can turn promising early molecular responses into a reproducible profile that stands out on both efficacy and tolerability across broader patient subsets.
What early CARDINAL trial signals may reveal and why the dataset still carries meaningful uncertainty
The CARDINAL study design helps explain why Merck & Co., Inc. may have felt comfortable moving early. TERN-701 is being studied in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia patients previously treated with at least one prior tyrosine kinase inhibitor and experiencing treatment failure, suboptimal response, or intolerance. Dose escalation completed without dose-limiting toxicities up to the maximum dose of 500 mg once daily, and dose expansion is underway, with an added cohort for patients with BCR::ABL1 resistance mutations including T315I and others.
That setup gives the program multiple shots on goal. If TERN-701 performs well in later-line or mutation-defined settings, it could establish an initial commercial niche even before any attempt to move earlier in treatment sequencing. But the same structure also creates important interpretive limits. Cross-trial comparisons in chronic myeloid leukemia are notoriously tricky because patient histories, mutation distributions, prior therapy exposure, and response definitions can vary meaningfully. What looks impressive in a heavily pretreated cohort may not translate neatly into a broader competitive narrative unless the eventual dataset is mature, internally consistent, and clinically interpretable.
Regulatory watchers will also want to see how the program handles the usual development pressure points. Early tolerability signals are helpful, but chronic myeloid leukemia is often managed over long durations, which means even modest toxicities can matter more than they might in shorter-course oncology settings. Convenience matters too. Oral administration is attractive, but convenience alone is no longer a differentiator unless it comes with cleaner monitoring, better adherence potential, or a simpler safety-management profile.
Why Merck may be buying development speed and optionality as much as it is buying a CML drug candidate
Another important dimension is operational. Terns Pharmaceuticals, Inc. brought the asset to this point, but Merck & Co., Inc. brings the infrastructure to globalize development, accelerate site expansion, support regulatory engagement, and prepare manufacturing and commercialization pathways earlier than a smaller biotech typically can. For an asset like TERN-701, that matters because time-to-positioning can influence both market relevance and strategic flexibility.
Merck & Co., Inc. is effectively buying optionality on multiple future narratives. The most straightforward is that TERN-701 becomes a differentiated later-line chronic myeloid leukemia therapy with a tolerability or efficacy edge. The more ambitious version is that the asset evolves into a best-in-class candidate capable of moving into earlier lines of therapy or into mutation-defined segments where current options leave dissatisfaction. There is also the possibility that the asset becomes valuable in combination strategies or in more tailored sequencing approaches as treatment algorithms continue to evolve.
Still, none of those outcomes is guaranteed. The proposed acquisition will be accounted for as an asset acquisition, with a roughly $5.8 billion charge expected in 2026. That accounting treatment is a reminder that Merck & Co., Inc. is absorbing substantial upfront risk for an asset that remains clinically unproven at the registrational level. If later studies disappoint, the transaction could quickly be reframed as an expensive example of pipeline urgency outrunning evidence maturity.
In that sense, this deal says as much about the current oncology business model as it does about TERN-701 itself. Big pharmaceutical companies are no longer waiting passively for certainty when the assets they want are scarce, mechanistically differentiated, and positioned in disease areas where good data can translate into durable market relevance. Merck & Co., Inc. appears to believe TERN-701 is one of those assets. The rest of the market will now watch whether the science can carry the valuation.
